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ABSTRACT
Non-malignant cells can be transformed via the acti-
vation of kinases that control degradation of neural-
restrictive silencer factor (REST). Here, we identify
a mechanism that contributes to the activation of
genes, expression of which is controlled by respon-
sive elements containing overlapping binding sites
for REST and nucleolin. We demonstrate that both
phosphorylated and non-phosphorylated nucleolin-
bound DNA; however, only phosphorylated nucleolin
successfully competed with either full-length REST
or a REST-derived DNA-binding peptide, REST68,
for binding to the overlapping binding sites. We
show that this interplay between the two transcrip-
tion factors regulates the activation of cell survival
and immunomodulatory genes in tumors and
non-malignant cells with activated protein kinase
C, which is accompanied with alterations in cell
proliferation and apoptosis. We propose a model
for the regulation of these genes, which brings a
new insight into the molecular mechanisms that
control cellular transformation driven by activation
of protein kinases.
INTRODUCTION
A number of studies demonstrated the central role that
protein kinases play in transformation of non-malignant
cells. Human mammary epithelial cell can be trans-
formed through activation of phosphatidylinositol
3-kinase (PI3K) (1). PI3K also regulates cellular growth
(2) and prevents apoptosis (3). Protein kinase Cn (PKCn)
has been implicated as a mediator of epidermal growth
factor receptor signaling in certain cell types. PKCn acti-
vation can transform non-malignant cells (4,5) resulting
in cancer cell growth, survival and metastasis (6–8).
The neural-restrictive silencer factor (REST), originally
described as a transcriptional repressor of neuronal
gene expression (9,10), has recently emerged as a tumor
suppressor capable of transforming epithelial cells
when mutated (11), or subsequent to degradation
of REST by b-TRCP ligase upon activation of cellular
phosphorylation (12). This latter process could be
triggered downstream of PI3K and PKC, which contrib-
ute to cellular transformation (1,5).
Recently, there has been an increased interest in using
thehostimmunesystemtotreatpatientswithmalignancies.
However, a recurring problem is that tumor cells often
escape from immune control by overexpressing
immunosuppressive molecules, such as membrane-bound
complement regulators (mCReg), or proteins that directly
impair immune responses to tumors (13,14). In many
tumors, mCReg expression is much greater than
on normal surrounding tissue (15–18). The role of CD59,
the only mCReg inhibitor of the cytolytic membrane
attack complex of complement system, in enhancing
tumor survival and growth in vivo was clearly demo-
nstrated (19), prompting the search for an eﬃcient
strategy for CD59 suppression in tumors. We identiﬁed
REST as an important regulator of the transcriptional
machinery of the cd59 gene. Guided by the central role of
REST in cellular transformation, we designed a peptide,
REST68, derived from the DNA-binding domain of
REST (18), which inhibited the expression of CD59 in
tumors expressing a mutated REST which lacks
DNA-binding activity.
Here, we identify nucleolin (NCL) as a key player in
the modulation of expression of CD59. We elucidate the
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tors that bind to overlapping sites within the promoters
of genes essential for cell survival and tumor growth. This
interplay causes the overexpression of the above genes,
exempliﬁed by cd59 and mcl1, in tumors and in
non-malignant cells where PKC is activated. We propose
a model for the regulation of genes with overlapping
REST/NCL binding sites in their promoters allowing
better understanding of the molecular machinery
involved in cellular transformation driven by activation
of protein kinases.
MATERIALS AND MEDHODS
Cell lines and treatments
Human neuroblastoma cell lines IMR32 and Kelly, the
human colon carcinoma cell line Caco2, the malignant
melanoma cell line G361 and the Chinese hamster ovary
(CHO) cells (all from the European Collection of Animal
Cell Cultures; ECACC) were maintained in RPMI 1640
with 10% heat-inactivated fetal calf serum (FCS), supple-
mented with glutamine, penicillin and streptomycin
(Invitrogen). CHO cells were transfected with expression
plasmids containing the full-length cDNAs for either
human NCL or human REST (OriGene) using jetPEI
reagent (Autogen Bioclear UK Ltd.). In some experi-
ments, the above cells were treated for 24 or 48h with
10mM GF109203X, an inhibitor of PKC family kinases
(Merck Chemicals Ltd.).
Normal human dermal ﬁbroblasts (HDF; Millipore)
were maintained in basal HDF medium with supplement
as recommended by the supplier. In some studies, HDF
cells were treated with 4mM PDBu (Merck) over a period
of 48h prior to and after transformation with lentiviral
particles to ensure maintenance of high protein kinase
C (PKC) activity. ReNcell VM human neural progenitor
cells (Millipore) were grown and diﬀerentiated as
described previously (20).
Preparation of nuclear extracts followed by pull-
down of proteins and mass spectrometry
identiﬁcation (21,22), western blotting (23,24), chromatin
immunoprecipitations (ChIPs) (Magna ChIP A kit;
Millipore), quantitative reverse transcription-PCR and
qPCR (primers used are given in Supplementary Table
S1) and ﬂow cytometry (25–27), were performed
as described previously. Expression of REST was
detected with rabbit polyclonal anti-REST antibody raised
against amino acids 1–290 of the protein (H-290; Santa
Cruz Biotechnology, Inc.). This antibody recognizes
both the full-length and truncated REST. REST68,
NCL and phosphorylated NCL were detected with
mouse monoclonal anti-His (Millipore), anti-NCL
(Millipore) and anti-NCL-phosphorylated (Thr76/Thr84)
(BioLegend). Phosphorylation of REST was determined
by anti-phosphoserine antibody (clone 4A4; Millipore).
To control for the amount of sample loaded, blots were
stained with polyclonal anti-b-actin antibody (Cambridge
Bioscience Ltd).
Electrophoretic mobility shift assay
DIG-labeled sense and antisense strands of the 35-bp
responsive element (RE) within the cd59 promoter were
purchased (Sigma–Aldrich). Oligonucleotides (100pmol
each) were mixed in equimolar amounts and
annealed(18). The annealed DNA probe (10pmol per
reaction) was incubated with 10mg of nuclear protein
extracts from CHO cells or CHO transfected with either
NCL- or REST-expressing plasmids. In some reactions, a
50-fold excess of non-labeled 35bp RE was included as
a control for speciﬁcity. To identify the presence of NCL
and REST in DNA–protein complexes, antibodies against
these two proteins were used. DNA was separated (28)
and detected with anti-DIG-AP Fab fragments (Roche
Diagnostics). For the NCL/REST displacement experi-
ments, the same amount of protein was used per
reaction (10mg); however, only 0.2pmol of the labeled
probe was added to ensure that no unbound DNA
would remain after the ﬁrst incubation with the nuclear
extract.
Subcloning of REST and preparation of reporter
constructs with mutated RE from the cd59 promoter
To enable generation of Kelly cells expressing the full-
length REST, we cut out the REST-coding sequence
from the OriGene plasmid using BamHI followed
by subsequent ligations with NotI–BamHI adaptor
(Supplementary Table S1) and NotI-digested
pDR2DEF1a expression plasmid. Clones with the
correct orientation (conﬁrmed by sequencing) were used
for transfection into Kelly cells. Transfected cells were
selected in medium containing hygromycin B (InvivoGen).
Cd59 promoter fragment, 2140-bp long, was previously
cloned into pEGFP-1 vector (Clontech), generating a
reporter system for studying the role of promoter
sequences in expression of the cd59 gene (18). To study
the interplay between REST and NCL transcription
factors, we generated two additional reporter constructs
in which the wild-type RE was mutated in such a manner
that it still binds REST but not NCL (mutCD59) or does
not bind either of the two transcription factors (replaced
by an irrelevant 35-bp sequence; irr35bp). To generate
these two constructs, we used the previously prepared
pEGFP-1 vector with the wild type cd59 promoter as a
template in overlapping PCR mutagenesis with
oligonucleotides given in Supplementary Table S1.
Sequences for the both constructs were designed based
on the previously published consensus binding sequences
for REST (29) and Sp1/NCL (30,31). Constructs were
transfected into diﬀerent cell types (Eﬀectene reagent;
Qiagen) and in some experiments transfected cells were
selected by G418 (Merck).
RNA interference
NCL was knocked down in IMR32 and Kelly cells by
transfecting the cells with pKD-Nucleolin-v1 plasmid
(Millipore) expressing siRNA speciﬁc for the NCL
mRNA. pKD-NegCon-v1 (Millipore) was used as a nega-
tive control. REST was knocked down in G361 and HDF
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siRNA speciﬁc for the REST mRNA (18) and transfected
cells were selected by puromycin (10ng/ml). Transfections
were performed using Eﬀectene reagent (Qiagen) follow-
ing the supplier’s recommendations. IMR32 and Kelly
cells with knocked down REST expression were generated
previously (18) using the same plasmids as for the G361
and HDF cells. The eﬀect of the NCL and REST knock-
down was assessed by qPCR 48h after the transfection.
To achieve a higher eﬃciency of the NCL
knockdown in G361 and HDF cells, a lentiviral
approach was used. Constructs were engineered based
on the pRRLSIN.cPPT.PGK-GFP.WPRE lentiviral
vector (Addgene), which expresses GFP. The h1
promoter together with the siRNA sequence from the
pKD-Nucleolin-v1 plasmid was excised using SpeI and
XhoI restriction enzymes and the residual fragment
ligated into pRRLSIN.cPPT.PGK-GFP.WPRE, which
contains the same unique restriction sites, using T4
ligase. The control siRNA sequence from pKD-NegCon-
v1in was inserted in a similar manner. To enable the detec-
tion of REST and NCL binding to certain promoters
using relatively low number of cells, fragments from
promoter sequences of the cd59, mcl1 and adcy5 genes
that contain REST/NCL binding sites (Supplementary
Table S1 and Supplementary Figure S2) were inserted
into both plasmids. The cd59 fragment was inserted into
the NruI restriction site, the mcl1 fragment into a BamHI
site and the adcy5 promoter fragment into a KpnI site.
Oligonucleotides for these three promoter sequences
(Biomers.net GmbH) were designed such that after
annealing, they formed cloning-ready ends. Restriction
enzymes, T4 ligase and NEB 5-alpha competent
Escherichia coli were purchased from New England
Biolabs. The correctness of all constructs was conﬁrmed
by sequencing. Lentiviral particles were prepared using
MISSION Lentiviral Packaging Mix (Sigma–Aldrich)
and stored at –80
oC until use.
Cell viability, apoptosis and cell proliferation assays
Cells transfected with either construct expressing
NCL-speciﬁc siRNA or a control plasmid were treated
with PDBu activator or the same volume of dimethyl
sulfoxide (DMSO) as described above. The percentage
of viable and apoptotic cells was determined by staining
with BD Cell Viability and PE Annexin V Apoptosis
Detection Kits (BD Pharmingen), respectively, following
the manufacturer’s recommendations. The eﬀect of each
treatment on cellular proliferation was assessed using
CyQUANT Direct Cell Proliferation Assay Kit
(Invitrogen).
Statistical analysis
The data are expressed as mean±SEM and were
analyzed for statistical signiﬁcance by the two-tailed
Student’s t-test to compare two paired groups of data.
P<0.05 was considered to be statistically signiﬁcant.
RESULTS
NCL is involved in the regulation of CD59 expression
Recently, we identiﬁed a 35-bp RE within the cd59
promoter containing the REST binding site, which is
involved in the overexpression of CD59 in neuroblastoma
(18). Here, we elucidate the molecular mechanism
resulting in the overexpression of CD59 in tumors by iden-
tifying transcription factors that bind to the RE. In our
study we used Kelly and IMR32 cells, human
neuroblastoma lines expressing high and low amounts of
CD59, respectively, and primary neurons diﬀerentiated
from human neural progenitor cells (REN), which have
a negligible CD59 expression (Figure 1A). Nuclear
extracts from all three cell types were generated and
proteins that bind to the 35-bp RE from the cd59
promoter were precipitated (Figure 1B). In each precipi-
tation, we observed three bands (marked by arrows);
however, the highest molecular weight band was
enriched in preparations from Kelly cells in comparison
to those from IMR32 and REN cells. Using mass
spectrometry, we unequivocally identiﬁed this protein
as NCL.
We next investigated whether NCL was involved in the
regulation of CD59 expression in living cells. Using
RNAi, NCL was knocked down in IMR32 and Kelly
cells with similar eﬃciency (75% decreased expression of
NCL at the RNA level) (Figure 1C). CD59 expression was
decreased by 80% following knockdown in Kelly cells, but
remained unaﬀected in IMR32 cells. A likely reason for
this result is that because IMR32 cells express full-length
REST binding of NCL to the RE is blocked, whereas in
Kelly cells which express the truncated REST isoform the
RE is unoccupied and NCL can bind. It is also possible
that the failure of NCL knockdown to aﬀect CD59
expression in IMR32 cells is a consequence of NCL
phosphorylation status. NCL is a heavily phosphorylated
protein substrate for PKCn and p34
cdc2 kinases (32,33).
To test this, western blots were performed (Figure 1D),
which showed that IMR32 and Kelly cells have similar
levels of expression of NCL; however, phosphorylation
of NCL is much lower in IMR32 cells as compared to
Kelly cells.
Phosphorylation of NCL plays a major role in competition
with REST for binding to DNA
To test the importance of NCL phosphorylation in its
binding to the DNA consensus sequence overlapping
with the REST binding site, we ﬁrst determined the
eﬀect of diﬀerent inhibitors of p34
cdc2 and PKCn kinases
on NCL phosphorylation (Supplementary Figure S1A).
The most remarkable inhibition was achieved by
GF109203X (GF), an inhibitor of PKC. Similar eﬀects
were observed with LY294002, an inhibitor of PI3K. We
chose to use GF in our further experiments. We detected
low levels of binding of NCL to the cd59 promoter in
IMR32 cells, while antibody against REST enriched the
chromatin fraction in the RE by 4-fold compared to the
input control (Figure 2A). Treatment of IMR32 cells with
GF led to a loss of NCL phosphorylation and abolished
Nucleic Acids Research,2010, Vol.38, No. 9 2801its binding to the cd59 promoter. In concert with this,
REST binding to the promoter was increased 34-fold
compared to binding in untreated cells. These events
resulted in a 4-fold decrease in CD59 expression in
IMR32 cells. To demonstrate interplay between REST
and NCL for their binding to the cd59 promoter, we per-
formed ChIP with chromatin fragments from IMR32 cells
in which REST was knocked down. This resulted in a
considerable decrease in REST binding to the promoter
and an 8-fold increase in NCL binding augmenting
expression of CD59 by 60%. To determine if the
detected binding occurred within the 35-bp RE of the
cd59 promoter, we designed a plasmid in which the RE
from the cd59 promoter was replaced with an irrelevant
35-bp sequence (irr35bp) that does not bind REST and
NCL (Supplementary Figure S2A). ChIP with chromatin
fragments from IMR32 and Kelly cells transfected with
plasmids containing either the wild-type promoter or the
irr35-bp sequence (Supplementary Figure S2B) showed
that this substitution abolished binding of both transcrip-
tion factors. This clearly demonstrated that the binding to
the cd59 promoter we detect in our ChIP experiments
Figure 1. NCL regulates expression of CD59. (A) qPCR (top) and ﬂow cytometry (bottom) analysis of expression of CD59 in REN neurons, IMR32
and Kelly neuroblastoma cells. RNA expression in REN cells was set as 100%. Columns, results from three independent experiments; bars, SEM. (B)
Coomassie-stained proteins from REN, IMR32 and Kelly nuclear extracts, binding to the 35-bp RE in the cd59 promoter. Beads without the RE
were used as a control for the background. Proteins were separated in NuPAGE 4–12% Bis–Tris gels. (C) qPCR analysis of expression of NCL and
CD59 in IMR32 and Kelly cells with knocked-down expression of NCL. Expression in cells transfected with a control plasmid was set as 100%.
Columns, results from three independent experiments; bars, SEM. (D) Western blots for expression of NCL, phosphorylated NCL (Thr76/Thr84)
and b-actin in IMR32 and Kelly cells. Equal amounts of nuclear protein extracts (40mg) were loaded in each lane.
2802 Nucleic Acids Research, 2010,Vol.38, No. 9Figure 2. Eﬀect of NCL phosphorylation on displacement of REST from the cd59 promoter. (A) IMR32 cells were treated with the GF inhibitor of
PKC kinases or transfected with plasmid expressing REST-speciﬁc siRNA, and the eﬀect of these treatments on expression of NCL, phosphorylated
NCL, REST and b-actin were examined by western blots (left). Equal amounts of nuclear protein extracts (40mg for NCL, phosphoNCL and b-actin;
120mg for REST) were loaded in each lane. The eﬀect of the treatments on REST and NCL binding to the 35-bp RE was determined by ChIP with
anti-REST and anti-NCL antibodies, respectively (middle). Binding was quantiﬁed by qPCR and was set as 1 for the input control of each treatment.
Immunoprecipitation with non-immune rabbit IgG was carried out as a control for the assay background. Columns, results from three independent
experiments; bars, SEM. Alterations in expression of CD59 following the treatments were quantiﬁed by qPCR (right). Expression in non-treated cells
was set as 100%. Columns, results from three independent experiments; bars, SEM. Similar experiments as in (A) were carried out with Kelly cells
(B) and Kelly cells transfected with plasmid expressing either the full-length REST (C) or REST68 peptide (D).
Nucleic Acids Research,2010, Vol.38, No. 9 2803requires presence of the 35-bp RE. Importantly, this
experiment also showed that binding of REST and NCL
to the wild-type cd59 promoter is not a function of poten-
tial cis elements ﬂanking the 35-bp RE.
Western blots showed that the GF treatment of IMR32
cells (Figure 2A) increased REST content compared to
non-treated cells, which supports the previous ﬁnding
that phosphorylation at the C-terminus of REST is
a signal for its degradation (12). Considering this, we
determined if the GF treatment contributes to changes
in the phosphorylation status of REST (Supplementary
Figure S1B). We performed western blots using equal
amounts of immunoprecipitated REST and monoclonal
antibody against phosphoserine, a posttranslational mod-
iﬁcation shown to be responsible for REST degradation
(12). These experiments showed that treatment of IMR32
cells with GF decreased phosphorylation in REST.
However, in Kelly cells we did not detect signiﬁcant
phosphorylation of the truncated REST expressed by
these cells. To show that this lack of phosphorylation in
REST is due to the expression of truncated isoform, we
carried out similar experiments with lysates from Kelly
cells transfected with plasmids expressing the full-length
REST. The full-length REST was heavily phosphorylated
and GF treatment led to marked decrease in
phosphorylation of this protein.
Taken together, the above experiments suggest that
serine phosphorylation occurs to a great extent within
the full-length REST and that GF inhibitor can inhibit
this phosphorylation resulting in accumulation of this
transcriptional suppressor. Therefore, the observed
decrease in NCL binding to the RE (Figure 2A) might
be, at least in part, a result of the increased amount of
REST protein. To address this issue, we carried out
similar experiments but with Kelly cells (Figure 2B),
which express only truncated REST that cannot be
degraded in response to phosphorylation (12). ChIP
analyses did not detect any diﬀerence in NCL binding to
the 35-bp RE, suggesting that in the absence of
full-length REST, the phosphorylation status of NCL is
not important for its interaction with DNA. The lack of
regulatory role of the truncated REST in expression
of CD59 was conﬁrmed by ChIP with chromatin frag-
ments from Kelly cells with knocked down REST, which
did not alter binding of NCL to the RE. As a conse-
quence, expression of CD59 was unaﬀected by the GF
treatment and REST knockdown (qPCR data). To
address if GF did not alter NCL binding in Kelly cells
due to the lack of full-length REST, we transfected
Kelly cells with plasmids expressing the full-length
REST and analyzed these cells for binding of REST and
NCL to the 35-bp RE (Figure 2C). In the presence of
full-length REST, which bound to the RE, NCL binding
was decreased 5-fold compared to untransfected Kelly
cells (Figure 2B). GF treatment abolished NCL binding
and increased the number of REST molecules bound to
the RE, which resulted in the inhibition of CD59
expression.
Next, we took advantage of a previously generated
Kelly cell line transfected with a plasmid that expresses
REST68, a peptide comprising the DNA-binding zinc
ﬁnger domains 6–8 of REST (18). REST68 binds DNA,
but does not contain the phosphorylation signal for deg-
radation, thus, its expression should not be aﬀected by
GF. This expectation was conﬁrmed by western blotting
(Figure 2D). Although the expression of REST68 was
unaltered by GF, ChIP analysis showed 5-fold less
binding of NCL to the 35-bp RE in GF-treated cells
compared to non-treated ones. The GF treatment
resulted in the replacement of NCL by REST68 and an
80% decrease in the expression of CD59. These data
clearly show that the phosphorylation status of NCL is
of major importance for the interplay between REST and
NCL when they bind to overlapping binding sites.
To elucidate if the REST/NCL interplay is a competi-
tion for binding to the overlapping binding sites within the
3- bp RE or co-recruitment, we carried out re-ChIP with
chromatin fragments from untreated Kelly cells or
transfected with REST expressing plasmid, incubated
with GF inhibitor or both together (Figure 3A). When
anti-NCL was used as ﬁrst antibody, we did not detect
any REST binding to the 35-bp RE with anti-REST
used in the second immunoprecipitation. When anti-
REST was the primary antibody, we detected binding
of REST to the 35-bp RE in Kelly cells transfected with
REST expression construct with or without GF treatment.
However, no binding of NCL was found in any of the
cells. These data unambiguously showed that REST and
NCL compete for binding to overlapping binding sites and
do not co-recruit.
We further addressed the importance of phospho-
rylation status of NCL for its competition with REST
for binding to overlapping binding sites by performing a
series of electrophoretic mobility shift assays (EMSAs;
Figure 3B and C). CHO cells were transfected with expres-
sion plasmids containing the full-length cDNAs for
human REST and NCL. We used cells from evolutionary
diverse specie to be able to perform competition assays for
binding of human REST and NCL to DNA and to avoid
complications that may occur by adding extracts that
contain both proteins. Cells were grown and treated
with GF. Prepared nuclear extracts were analyzed for
expression and phosphorylation status of REST and
NCL (Figure 3B). The antibody against REST recognized
only the human protein and not the endogenous hamster
protein; GF treatment slightly increased the expression of
human REST. BLAST search shows that NCL is highly
conserved, and the antibody against human NCL also
recognized hamster NCL. However, transfection of
CHO cells with human NCL-expressing vector markedly
increased the amount of protein detected by the antibody,
conﬁrming that human NCL was expressed. We per-
formed densitometry analysis of phospho-NCL band
intensities for untreated and GF-treated CHO cells.
Similar analysis was carried out for CHO cells transfected
with plasmids expressing either REST or NCL (Figure 3B,
right). We obtained similar ratios for all three cell lines,
suggesting that phosphorylation of both hamster and
human NCL is similarly inhibited by the GF treatment.
EMSA of the 35-bp RE with nuclear extracts from
untransfected CHO cells, untreated or treated with GF,
showed only a single band, which was shown by supershift
2804 Nucleic Acids Research, 2010,Vol.38, No. 9Figure 3. REST/NCL competition for binding to the 35-bp RE: phosphorylated NCL displaces REST from the 35-bp RE in EMSA. (A) Re-ChIP
with chromatin fragments from untreated Kelly cells or transfected with REST-expressing plasmid, incubated with GF inhibitor or both together.
Either anti-NCL or anti-REST was used as ﬁrst antibody, followed by second ChIP with anti-NCL, anti-REST and non-immune rabbit IgG as
background control. Binding was quantiﬁed by qPCR and was set as 1 for the input control of each treatment. Columns, results from three
independent experiments; bars, SEM. (B) Nuclear extracts from non-treated CHO cells or cells transfected with either a REST or NCL expression
plasmid were analyzed by western blots (left) for expression of REST, NCL and phosphorylated NCL using antihuman antibodies. Similar analysis
was performed for the above cells, after they were treated 24h with 10-mM GF inhibitor. Ratios between band intensities for phospho-NCL without
and with GF treatment were calculated for each cell line using densitometry analysis (right). Columns, results from three independent experiments;
bars, SEM. (C) EMSA with the 35-bp RE labeled with DIG (10pmol/reaction), incubated with 10mg of nuclear protein extracts from cells described
in (B) in the presence of 0.1mg/ml poly(deoxyinosinicdeoxycytidylic acid) and 1mg/ml salmon sperm DNA. Antibodies against either REST or NCL
were added in some reactions (+) to test for presence of these two proteins in the observed complexes. The complexes were separated in a 2.5%
agarose gel for 2h at 100V, transferred onto a nylon membrane and detected by anti-DIG-AP Fab fragments. (D) EMSA demonstrating the NCL/
REST competition for binding to the 35-bp RE. Labeled probe (0.2pmol/reaction; no unbound DNA remains after the incubation) was incubated
with nuclear protein extracts (10mg/reaction) from CHO cells expressing either human NCL or REST, treated or untreated with GF. Complexes
obtained after incubation of the 35-bp RE with CHO cells expressing human REST and treated with GF were subjected to competition with nuclear
extracts from CHO cells expressing human NCL with or without GF treatment.
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cells expressing human REST gave two bands. Supershift
with anti-NCL and anti-REST showed that the complex
with the higher electrophoretic mobility contained NCL,
while the slower migrating band contained REST. In
untreated cells, both bands had comparable intensity;
however, when the transfected cells were treated with
GF, the intensity of the NCL complex was markedly
reduced (Figure 3C).
Once the distinct binding pattern of each nuclear extract
to the 35-bp RE was established, we explored whether
NCL could replace REST in preformed complexes
(Figure 3D). First, we optimized the concentration of
the 35-bp RE to ensure that there was no residual
unbound DNA after the initial formation of complexes
by incubating the DNA with nuclear extracts from CHO
cells expressing human REST. We ﬁnally added nuclear
extracts from CHO cells expressing human NCL, with or
without GF, to the preformed complexes. The majority of
the REST–DNA complex was replaced with NCL–DNA
when extracts without GF were added (Figure 3D; lanes
3 and 4); however, when the NCL was not phosphorylated
(Figure 3D; lane 5), this shift was not observed. This
experiment conﬁrms the critical role of NCL
phosphorylation in the REST/NCL competition for
binding to overlapping binding sites.
Interplay between REST and NCL is a key mechanism in
gene activation by PKC
Considering the high number of genes regulated by REST
[binding sites mapped to 1946 locations (34)], we reasoned
that REST/NCL interplay might be involved in the regu-
lation of many genes in which the two transcription
factors have overlapping binding sites. This issue is of
particular importance to tumor biology considering
that REST is a major player in cellular transformation
upon increased phosphorylation (12). We ﬁrst studied
REST/NCL interplay in G361 melanoma cells, a tumor
type that originates from neural crest like neuroblastoma,
however, unlike the neuroblastoma cells express the
full-length DNA-binding form of REST (18,35). G361
cells were infected with lentiviral particles containing
plasmids that express GFP and either siRNA
for knocking down NCL (NCL-RNAi) or a control
sequence (cntr-RNAi). Both plasmids also contained frag-
ments from the promoters of cd59, mcl1 and adcy5, each
including a REST binding site. NCL was recently shown
to bind to Sp1 binding sequences in DNA (31) and here
we demonstrated that the Sp1 binding sites are required
for binding of NCL to the 35-bp RE (Supplementary
Figure S2A and B). The REST binding site overlaps
with a NCL binding sequence in the mcl1 and cd59, but
not in the adcy5 promoter fragments (Supplementary
Figure S2C). An average multiplicity of infection (MOI)
of around 15–16 was achieved (Supplementary Figure S3),
which allowed performing the subsequent analyses with
a relatively low number of cells (710
6) sorted by
expression of GFP (Figure 4). The knockdown caused
decreased expression of NCL at both the RNA (by
90%) and protein level. This reduced expression led to
Figure 4. Interplay between REST and NCL regulates expression of
genes with overlapping REST/NCL-binding sites in melanoma
tumors. (A) G361 cells were infected with lentiviral particles expressing
either siRNA speciﬁc for NCL or a control siRNA. Infected cells
(expressing GFP) were separated by ﬂow sorting, and the eﬀect of
this knockdown on the expression of NCL, phosphorylated NCL,
REST and b-actin were examined by western blots. Equal amounts
of nuclear protein extracts were loaded in each lane. (B) The eﬀect of
NCL knockdown on REST and NCL binding to the promoters of
cd59, mcl1 and adcy5 was determined by ChIP with anti-REST and
anti-NCL antibodies, respectively. Binding was quantiﬁed by qPCR
and was set as 1 for the input control of each treatment.
Immunoprecipitation with non-immune rabbit IgG was carried out as
a control for the assay background. Columns, results from three inde-
pendent experiments; bars, SEM. (C) Alterations in expression of NCL,
CD59, Mcl1 and ADCY5 as a result of the NCL knockdown were
quantiﬁed by qPCR. Expression in control cells was set as 100%.
Columns, results from three independent experiments; bars, SEM.
2806 Nucleic Acids Research, 2010,Vol.38, No. 9an 8-fold lower binding of NCL to mcl1 and cd59 pro-
moters (Figure 4B). Depletion of the NCL from these
promoters allowed increased binding of REST (3.5- to
4-fold) and a 60% decrease in the expression of the cd59
and mcl1 genes (Figure 4C). Primers for the assessment of
Mcl1 expression were designed to detect only the longer
splice variant, which stimulates cell survival. No binding
of NCL to the adcy5 promoter was detected, and we did
not observe any alteration in the binding of REST or in
the expression level of the adcy5 gene following the NCL
knockdown.
These data show that the interplay between REST and
NCL is a key mechanism in tumors for the regulation of
the expression of genes with overlapping binding sites in
their promoters for these two transcription factors. The
data also show that the REST/NCL interplay controls the
expression of genes involved in cell survival (i.e. mcl1;
similar results for bcl2l1, not shown) and modulation of
immune responses and tumor growth (cd59). Thus, our
next aim was to determine if this interplay is involved in
gene overexpression occurring during cellular transforma-
tion by PKC (5). Primary HDFs were infected at a MOI of
12 (Supplementary Figure S3), with either NCL-RNAi or
cntr-RNAi plasmids. In some experiments, HDFs were
treated for 48h with an activator of PKC, PDBu, prior
to infection. Western blots showed that the PDBu
Figure 5. REST/NCL interplay is involved in gene overexpression occurring during cellular transformation by PKC. (A) HDF cells, treated with
either the PDBu activator of PKC or DMSO as a control, were infected with lentiviral particles expressing either siRNA speciﬁc for NCL or a
control siRNA. Infected cells were separated by ﬂow sorting, and the eﬀect of this knockdown and/or PKC activation on the expression of NCL,
phosphorylated NCL and REST were examined by western blots. Equal amounts of nuclear protein extracts were loaded in each lane. (B) The eﬀect
of NCL knockdown and/or PDBu treatment on REST and NCL binding to the promoters of cd59, mcl1 and adcy5 was determined by ChIP with
anti-REST and anti-NCL antibodies, respectively. Binding was quantiﬁed by qPCR and was set as 1 for the input control of each treatment.
Immunoprecipitation with non-immune rabbit IgG was carried out as a control for the assay background. Columns, results from three independent
experiments; bars, SEM. (C) Alterations in expression of NCL, CD59, Mcl1 and ADCY5 as a result of the NCL knockdown and/or PKC activation
were quantiﬁed by qPCR. Expression in control cells was set as 100%. Columns, results from three independent experiments; bars, SEM.
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cells, which, in general, do not contain many
phosphorylated molecules (Figure 5A). Notably, PDBu
treatment resulted in a lower amount of REST at the
protein level, most likely a result of increased protein deg-
radation (12). Knocking down NCL expression by 85%
(Figure 5C) resulted in a 60% decrease in its binding to the
cd59 and mcl1 promoters (Figure 5B). PDBu treatment
resulted in 25-fold more NCL binding to the promoters
of cd59 and mcl1, a consequence of both the increased
phosphorylation of NCL and the degradation of REST.
Indeed, knockdown of NCL in PDBu-treated HDF
cells caused a considerable decrease in the binding of
this protein to the promoters and increased binding
of REST. However, REST binding was still lower
than in the control HDF cells, likely a consequence of
REST degradation following PDBu treatment. Critically,
knocking down NCL expression in PDBu-treated HDF
cells resulted in a 7-fold reduction of CD59 and Mcl1
mRNA expression compared to PDBu-treated cells
infected with the control virus (Figure 5C). This result
unambiguously showed that the interplay between
REST and NCL controls the activation of a set of
key genes in non-malignant cells upon activation
of PKC, a process which is implicated in cellular
transformation.
It is well-known that NCL has numerous functions
including that of a histone chaperone (36). To clarify
whether NCL exerts its main eﬀect on CD59 expression
by binding to the 35-bp RE, we generated EGFP-reporter
constructs in which expression of EGFP was controlled by
the wild-type cd59 promoter or a mutated one in which the
35-bp RE still binds REST but not NCL (mutCD59)
(Supplementary Figure S2A). G361 malignant melanoma
cells transfected with the mutated or the wild-type cd59
promoter reporter constructs (Figure 6) demonstrated the
need of NCL binding sites within the 35-bp RE for the
increased gene expression.
Interplay between REST and NCL regulates cellular
proliferation and apoptosis
Considering that the interplay between REST and NCL
regulates expression of genes involved in cell survival and
apoptosis, we next decided to test the eﬀect of the NCL
knockdown alone or together with REST knockdown on
major cellular processes, resulting in tumor growth.
Knockdown eﬃciency of REST in G361 and HDF cells
was similar to that obtained for NCL (around 85%;
Figures 4C, 5C and 7A). Double knockdown of REST
and NCL restored expression of CD59 to levels similar
to these in corresponding controls (Figure 7A).
Unfortunately, we could not perform clonal growth in
soft agar, because this assay requires a relatively long
culturing of cells (1–2 weeks), while an eﬃcient knock-
down of the NCL expression results in cell death within
several days. Viability of G361 and HDF cells remained
unaﬀected within ﬁrst 48h after diﬀerent treatments
(Figure 7B). Therefore, we assessed the percentage of
apoptotic cells in G361 malignant melanoma and HDF
non-malignant cells as a result of NCL knockdown or
REST/NCL double knockdown (Figure 7C) 48h after
the treatments. Knockdown of NCL increased the
number of annexin V positive G361 cells by 3.5-fold,
while for the non-malignant HDF cells this increase was
around 1.3-fold only. To address if the phosphorylation
status of NCL is important for the observed lack of sig-
niﬁcant alteration in percentage of apoptotic HDF cells,
we treated cells with PDBu prior to the NCL knockdown.
Two days after that we found that the NCL knockdown
resulted in 4-fold increase in percentage of annexin V
positive cells, which well correlated with the results
obtained for the G361 cells. However, double knockdown
of REST and NCL in these cell lines took the percentage
of apoptotic cells back to levels similar to these in control
cells transfected with plasmid expressing cntr-siRNA.
The increased percentage of apoptotic cells because of
NCL knockdown correlated with a slower proliferation
rate of the G361 tumor cells and the PDBu-treated
HDF cells (Figure 7D). However, no signiﬁcant slow
down in proliferation of HDF cells was observed as
a result of the NCL knockdown. To demonstrate further
that the interplay between REST and NCL regulates cell
proliferation, we carried out double knockdown of REST
and NCL in the above cell lines, which restored prolifer-
ation rates to those characteristic for the control cells.
Figure 6. NCL exerts its eﬀect on CD59 expression by binding to the
35-bp RE. Two EGFP-reporter constructs were generated: in one of
them expression of EGFP is controlled by the wild-type cd59 promoter
(wtCD59 promoter); in the other construct, the 35-bp RE was mutated
in such a way that it still binds REST but not NCL (mutCD59
promoter) (Supplementary Figure S2A). Expression of EGFP in
G361 transfected with each of these two constructs was determined
by ﬂow cytometry. Promoterless pEGFP-1 vector was used as a
negative control. Promoter of the constitutively active elongation
factor alpha 1 (EFa1) was introduced in the pEGFP-1 and used as a
positive control. Columns, results from three independent experiments;
bars, SEM.
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REST is a transcriptional repressor that regulates
numerous genes, notably those involved in neuronal dif-
ferentiation and cellular transformation (12,37). The
essential role of this repressor in cellular transformation
was found to be controlled via the phosphorylation of a
conserved degron at the C-terminus of the protein,
initiating its degradation by SCF
bTRCP ligase (12). In
this study, we have identiﬁed a novel mechanism that con-
tributes to the regulation of a large number of genes con-
trolled by REST, which have overlapping binding sites for
REST and a second important transcription factor, NCL,
which requires Sp1 binding sites for its direct interaction
with DNA (31). A number of key genes, including those
encoding proteins regulating immune responses and
tumor growth (e.g. cd59) (18) and cell survival (mcl1,
bcl2l1), belong to this group of REST/NCL-regulated
genes (Supplementary Figure S2). It has been
demonstrated that activation of PI3K and PKCn protein
kinases can transform non-malignant cells (1,5). The
increased kinase activity not only leads to the degradation
of REST(12), but also phosphorylates NCL (5).
Phosphorylation of NCL allows displacement of the
remaining transcriptional suppressor from the promoter,
which further increases the expression of the gene
(Figures 2 and 3). Our experiments with knocked down
NCL (Figures 4 and 5) unambiguously showed that the
lack of NCL results in increased binding of REST to gene
Figure 7. Eﬀect of NCL knockdown on cellular proliferation and apoptosis. G361 malignant melanoma and HDF cells transfected with plasmids
expressing control siRNA or REST-speciﬁc siRNA were selected by puromycin. Selected cells were infected with lentiviral particles expressing either
siRNA speciﬁc for NCL or a control siRNA. In some experiments HDF cells were pre-treated with the PDBu activator of PKC 48h prior the
infection. Infected cells were separated by ﬂow sorting, and the eﬀect of this knockdown and PDBu treatment on the REST and CD59 expression
(A), cell viability (B), apoptosis (C) and proliferation (D) were studied by qPCR, BD Cell Viability Kit, Annexin V staining and CyQUANT Direct
Cell Proliferation Assay Kit (210
4 cells/well), respectively. Columns, data from three independent experiments; bars, SEM.
Nucleic Acids Research,2010, Vol.38, No. 9 2809promoters and reduced activation of REST/NCL con-
trolled genes. The overall eﬀect of this inhibited expression
of genes involved in cell survival was that cells slowed
down their proliferation and became more susceptible to
apoptosis (Figure 7). These eﬀects on proliferation and
apoptosis were however reversed by simultaneous knock-
down of both REST and NCL.
The above results, together with our previously pub-
lished data, enabled us to propose a model for the
upregulation of expression of genes with overlapping
REST/NCL binding sites in their promoters upon activa-
tion of protein kinases (Figure 8). In non-malignant cells,
REST is expressed at a relatively high level, and NCL
phosphorylation is moderate compared to transformed
cells. Thus, REST is bound to the gene promoters.
However, upon activation of kinases like PKCn, p34
cdc2
and PI3K, which occurs in cellular transformation
(1,5,38), NCL is phosphorylated and the half-life of
REST decreases as a consequence of its increased degra-
dation (12). These events cause decreased binding of
REST and increased binding of NCL to the overlapping
binding sites in the gene promoter (Figure 8A). Treatment
of such tumors with the REST68 peptide, degradation of
which is not aﬀected by phosphorylation, suppresses
expression of the gene by competing with phosphorylated
nucleolin. However, if cells are treated further with inhib-
itors of the protein kinases that use NCL as a substrate,
the amount of endogenous REST increases which together
with the REST68 peptide and inhibited phosphorylation
of NCL results in additional inhibition of gene expression.
Many tumors do not express the full-length REST
(Figure 8B), either due to an insertion that intro-
duces a stop codon and results in the expression of non-
DNA-binding truncated REST (39,40), or by deletion of
the gene during tumorigenesis (11). In the absence
of functional REST, both phosphorylated and non-
phosphorylated NCL bind to the gene promoter and acti-
vates expression via formation of complexes with other
transcription factors (i.e. c-Jun/NCL) (31). Treatment of
tumors with kinase inhibitors will therefore not
signiﬁcantly aﬀect expression of the genes controlled by
the REST/NCL interplay (Figure 2B, Supplementary
Figure S4). However, treatment of such tumors with a
peptide that binds the REST binding site (i.e. REST68)
will inhibit the expression of the target genes by competing
with phosphorylated NCL for binding to the overlapping
binding sites. Inhibition of NCL phosphorylation will
further enhance the binding of REST68 to the promoter
Figure 8. A model for regulation of genes with overlapping REST/NCL binding sites. (A) In malignant cells, protein kinases such as PI3 and PKC
are activated resulting in degradation of the full-length REST that binds to a responsive element within the promoter of the gene and in
phosphorylation of NCL, which together leads to a displacement of the remaining REST from the gene promoter and high expression levels.
Treatment of such tumors with the REST68 peptide (degradation is not aﬀected by phosphorylation) suppresses expression of the gene by competing
with phosphorylated NCL. However, if cells are treated further with inhibitors of NCL phosphorylation, NCL will no longer be in competition for
binding and gene expression will be suppressed further. (B) The model is similar to the one shown in (A); however, tumor types like colon carcinoma,
neuroblastoma and small-cell lung carcinoma lack REST that can bind to DNA and suppress gene expression. In these tumors, both phosphorylated
and non-phosphorylated NCL can bind to the gene promoter and activate expression. REST68 treatment prevents non-phosphorylated NCL from
binding to the REST/NCL overlapping binding sites, partially decreasing the expression. Hence, further treatment with kinase inhibitors does not
allow for competition between REST68 and NCL, resulting in even stronger inhibition of the controlled gene.
2810 Nucleic Acids Research, 2010,Vol.38, No. 9by taking the NCL out of the competition with this
peptide, leading to further suppression of the genes with
overlapping REST/NCL-binding sites.
Our data demonstrate a new mechanism involving
interplay between two transcription factors and
phosphorylation status that play a major role in the reg-
ulation of expression of genes involved in tumor growth
and survival. The current study provides a model, which
allows a better understanding of the molecular machinery
involved in cellular transformation driven by activation of
protein kinases and enables a better design of adjuvant
treatments for achieving eﬃcient suppression of survival
and immunomodulatory genes controlled by the REST/
NCL interplay.
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